A First-in-human and Proof-of-concept Study to Assess the Safety, Tolerability and Immunogenic Response of CV-MG01, Acetylcholine Receptor Mimetic Peptides, as Potential Therapeutic Vaccine, in Patients With Myasthenia Gravis

Trial Profile

A First-in-human and Proof-of-concept Study to Assess the Safety, Tolerability and Immunogenic Response of CV-MG01, Acetylcholine Receptor Mimetic Peptides, as Potential Therapeutic Vaccine, in Patients With Myasthenia Gravis

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2017

At a glance

  • Drugs CV MG01 (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; First in man; Pharmacodynamics; Proof of concept
  • Sponsors CuraVac
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 May 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
    • 11 May 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top